相似文献
1
Estrogen signaling crosstalk: Implications for endocrine resistance in ovarian cancer.
J Steroid Biochem Mol Biol. 2014 Sep;143:160-73. doi: 10.1016/j.jsbmb.2014.02.010. Epub 2014 Feb 22.
2
Anticancer effect of genistein on BG-1 ovarian cancer growth induced by 17 β-estradiol or bisphenol A via the suppression of the crosstalk between estrogen receptor α and insulin-like growth factor-1 receptor signaling pathways.
Toxicol Appl Pharmacol. 2013 Nov 1;272(3):637-46. doi: 10.1016/j.taap.2013.07.027. Epub 2013 Aug 8.
3
Therapeutic utility of natural estrogen receptor beta agonists on ovarian cancer.
Oncotarget. 2017 Jul 25;8(30):50002-50014. doi: 10.18632/oncotarget.18442.
4
Active Estrogen Receptor-alpha Signaling in Ovarian Cancer Models and Clinical Specimens.
Clin Cancer Res. 2017 Jul 15;23(14):3802-3812. doi: 10.1158/1078-0432.CCR-16-1501. Epub 2017 Jan 10.
5
Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators.
Cancer Chemother Pharmacol. 2005 Nov;56 Suppl 1:10-20. doi: 10.1007/s00280-005-0108-2.
6
Biological mechanisms and clinical implications of endocrine resistance in breast cancer.
Breast. 2011 Oct;20 Suppl 3:S42-9. doi: 10.1016/S0960-9776(11)70293-4.
7
Amplified Crosstalk Between Estrogen Binding and GFR Signaling Mediated Pathways of ER Activation Drives Responses in Tumors Treated with Endocrine Disruptors.
Recent Pat Anticancer Drug Discov. 2018;13(4):428-444. doi: 10.2174/1574892813666180720123732.
8
Stabilization of MORC2 by estrogen and antiestrogens through GPER1- PRKACA-CMA pathway contributes to estrogen-induced proliferation and endocrine resistance of breast cancer cells.
Autophagy. 2020 Jun;16(6):1061-1076. doi: 10.1080/15548627.2019.1659609. Epub 2019 Sep 6.
9
Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk.
Endocr Relat Cancer. 2006 Dec;13 Suppl 1:S15-24. doi: 10.1677/erc.1.01273.
10
Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo.
Clin Cancer Res. 2012 Nov 1;18(21):5911-23. doi: 10.1158/1078-0432.CCR-12-1257. Epub 2012 Aug 15.
引用本文的文献
1
Chromosome-length genome assembly of and gene expression data reveal fast pace-of-life comes with environmental stability.
bioRxiv. 2025 Jun 9:2025.05.28.656178. doi: 10.1101/2025.05.28.656178.
2
Tumour-derived exosome SNHG17 induced by oestrogen contributes to ovarian cancer progression via the CCL13-CCR2-M2 macrophage axis.
J Cell Mol Med. 2024 May;28(9):e18315. doi: 10.1111/jcmm.18315.
3
From desert flora to cancer therapy: systematic exploration of multi-pathway mechanisms using network pharmacology and molecular modeling approaches.
Front Pharmacol. 2024 Apr 11;15:1345415. doi: 10.3389/fphar.2024.1345415. eCollection 2024.
4
The prognostic value of MEK pathway-associated estrogen receptor signaling activity for female cancers.
Br J Cancer. 2024 May;130(11):1875-1884. doi: 10.1038/s41416-024-02668-w. Epub 2024 Apr 6.
5
From seeds to survival rates: investigating 's potential against ovarian cancer through network pharmacology.
Front Pharmacol. 2023 Oct 30;14:1285258. doi: 10.3389/fphar.2023.1285258. eCollection 2023.
6
Tailoring Potential Natural Compounds for the Treatment of Luminal Breast Cancer.
Pharmaceuticals (Basel). 2023 Oct 16;16(10):1466. doi: 10.3390/ph16101466.
7
Diabetes risk reduction diet and ovarian cancer risk: an Italian case-control study.
Cancer Causes Control. 2023 Sep;34(9):769-776. doi: 10.1007/s10552-023-01722-x. Epub 2023 May 24.
8
Impact of estrogen receptor expression on prognosis of ovarian cancer according to antibody clone used for immunohistochemistry: a meta-analysis.
J Ovarian Res. 2022 May 24;15(1):63. doi: 10.1186/s13048-022-01001-4.
9
Estrogen Receptor-Beta2 (ERβ2)-Mutant p53-FOXM1 Axis: A Novel Driver of Proliferation, Chemoresistance, and Disease Progression in High Grade Serous Ovarian Cancer (HGSOC).
Cancers (Basel). 2022 Feb 22;14(5):1120. doi: 10.3390/cancers14051120.
10
Gender Differences in Diabetic Kidney Disease: Focus on Hormonal, Genetic and Clinical Factors.
Int J Mol Sci. 2021 May 28;22(11):5808. doi: 10.3390/ijms22115808.
本文引用的文献
1
Origin and molecular pathogenesis of ovarian high-grade serous carcinoma.
Ann Oncol. 2013 Dec;24 Suppl 10:x16-21. doi: 10.1093/annonc/mdt463.
2
Estrogen responsiveness of the TFIID subunit TAF4B in the normal mouse ovary and in ovarian tumors.
Biol Reprod. 2013 Nov 14;89(5):116. doi: 10.1095/biolreprod.113.111336. Print 2013 Nov.
3
Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer.
J Transl Med. 2013 Sep 17;11:215. doi: 10.1186/1479-5876-11-215.
4
Notch signaling: targeting cancer stem cells and epithelial-to-mesenchymal transition.
Onco Targets Ther. 2013 Sep 6;6:1249-59. doi: 10.2147/OTT.S36162.
5
Estradiol and tamoxifen induce cell migration through GPR30 and activation of focal adhesion kinase (FAK) in endometrial cancers with low or without nuclear estrogen receptor α (ERα).
PLoS One. 2013 Sep 9;8(9):e72999. doi: 10.1371/journal.pone.0072999. eCollection 2013.
6
Tracking NF-κB activity in tumor cells during ovarian cancer progression in a syngeneic mouse model.
J Ovarian Res. 2013 Sep 10;6(1):63. doi: 10.1186/1757-2215-6-63.
7
Biology and therapeutic potential of PI3K signaling in ER+/HER2-negative breast cancer.
Breast. 2013 Aug;22 Suppl 2(0 2):S12-8. doi: 10.1016/j.breast.2013.08.001. Epub 2013 Sep 5.
8
The G-protein coupled estrogen receptor (GPER/GPR30) is a gonadotropin receptor dependent positive prognosticator in ovarian carcinoma patients.
PLoS One. 2013 Aug 9;8(8):e71791. doi: 10.1371/journal.pone.0071791. eCollection 2013.
9
Anticancer effect of genistein on BG-1 ovarian cancer growth induced by 17 β-estradiol or bisphenol A via the suppression of the crosstalk between estrogen receptor α and insulin-like growth factor-1 receptor signaling pathways.
Toxicol Appl Pharmacol. 2013 Nov 1;272(3):637-46. doi: 10.1016/j.taap.2013.07.027. Epub 2013 Aug 8.
10
Crosstalk between PKCα and Notch-4 in endocrine-resistant breast cancer cells.
Oncogenesis. 2013 Aug 5;2(8):e60. doi: 10.1038/oncsis.2013.26.
Zotero 插件